References
- AhujaMDhakeASSharmaSKMajumdarDKTopical Ocular Delivery of NSAIDsAAPS J2008425
- McColginAZHeierJSControl of intraocular inflammation associated with cataract surgeryCurr Opin Ophthalmol2000113610724825
- PerryHDDonnenfeldEDAn update on the use of ophthalmic ketorolac tromethamine 0.4%Expert Opin Pharmacother2006719910716370927
- ChangJHChungHNon-steroidal anti-inflammatory drug and endotoxin induced unveitisKorean J Ophthalmol1993735428189632
- PolanskyJRWeinrebRNSteroids as anti-inflammatory agentsPharmacology of the EyeSearsMLSpringer-VerlagNew York1984460538
- CampbellWBHalushkaPVLipid-derived autacoids: eicosanoids and platelet-activating factorHardmanJGLimbirdLEMolinoffPBGoodman and Gilman’s The Pharmacological Basis of Therapeutics9th edNew York, NYMcGraw-NetHill1996601616
- DonnenfeldEDDonnenfeldAGlobal experience with Xibrom (bromfenac ophthalmic solution) 0.09%: the first twice-daily ophthalmic nonsteroidal anti-inflammatory drugInt Ophthalmol Clin2006464214017060789
- OkaTShearerTRAzumaMInvolvement of cyclooxygenase-2 in rat models of conjunctivitisCurr Eye Res200429273415370364
- McGheeCNDeanSDanesh-MeyerHLocally administered ocular corticosteroids: benefits and risksDrug Saf200225335511820911
- SamiyNFosterCSThe role of non-steroidal anti-inflammatory drugs in ocular inflammationInt Ophthalmol Clin1996361952068778065
- FlachAJTopical nonsteroidal anti-inflammatory drugs in ophthalmologyInt Ophtalmol Clin200242111
- RojanasakulYRobinsonJRTransport mechanisms of the cornea: characterization of barrier permselectivityInt J Pharm198955237246
- SchalnusRTopical nonsteroidal anti-inflammatory therapy in ophthalmologyOphthalmologica2003217899812592044
- GuptaMMajumdarDKEffect of concentration, pH and preservatives on in vitro transcorneal permeation of ibuprofen and flurbiprofen from non-buffered aqueous dropsIndian J Exp Biol1997358448499475059
- AhujaMDhakeASMajumdarDKEffect of formulation factors on in vitro permeation of diclofenac from experimental and marketed aqueous eye drops through excised goat corneaYakugaku Zasshi20061261369137517139162
- Voltaren Ophthalma® (diclofenac) [package insert]Duluth, GANovartis Ophthalmics2003
- Acular® (ketorolac) [package insert]Irvine, CAAllergan Inc2002
- Nevanac® (nepafenac) [package insert]Fort WorthAlcon Laboratories2005
- Xibrom® (bromfenac) [package insert]Irvine, CAISTA Pharmaceuticals, Inc2006
- O’BrienTPEmerging guidelines for the use of NSAID therapy to optimize cataract surgery and patient careCurr Med Res Opin2005211131113716004683
- HeierJSToppingTMBaumannWKetorolac versus prednisolone versus combination therapy in the treatment of acute pseudophakic cystoid macular edemaOphthalmology20001072034203911054327
- RobertsCWBrennanKMA comparison of topical dicolfenac with prednisolone for postcataract inflammationArch Ophthal19951137257277786212
- El-HaraziSMRuizRSFeldmanRMA randomized double-masked trial comparing ketorolac tromethamine 0.5%, diclofenac sodium 0.1%, and prednisolone acetate 1% in reducing post-phacoemulsification flare and cellsOphthalmic Surg Lasers1998295395449674003
- FlachAJNonsteroidal anti-inflammatory drugsTasmanWDuane’s foundations of clinical ophthalmologyPhiladelphia (PA)Lippincott1994132
- WolfEJBraunsteinAShihCBraunsteinREIncidence of visually significant pseudophakic macular edema after uneventful phacoemulsification in patients treated with nepafenacJ Cataract Refract Surg200793391546154917720068
- HsuJKJohnstonWTReadRWHistopathology of corneal melting associated with diclofenac use after refractive surgeryJ Cataract Refract Surg20032925025612648633
- KeT-LGraffGSpellmanJMYanniJMNepafenac a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: II. In vitro bioactivation and permeation of external ocular barriersInflammation20002437138410850858
- BrownHBTaylorPMuscarinic receptor agonists and antagonistsHardmanJGLimbirdLEMolinoffPBRuddonRWGoodman and Gilman’s The Pharmacological Basis of Therapeutics9th edNew YorkMcGraw-Hill1996141160
- SancilioLFNolanJCWagnerLEWardJWThe analgesic and anti-inflammatory activity and pharmacologic properties of bromfenacArzneimittelforschung1987375135193497637
- WalshDAMoranHWShambleeDAAntiinflammatory agents. 3. Synthesis and pharmacological evaluation of 2-amino-3-benzoylpheylacetic acid and analoguesJ Med Chem198427137913886436487
- Data on file. ISTA Pharmaceuticals, Inc.
- WaterburyLDSillimanDJolasTComparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodiumCurr Med Res Opin2006221133114016846546
- YanniJMGraffGHellbergMRTopically administrable compositions containing 3-benzoylphenylaceteic acid derivatives for treatment of ophthalmic inflammatory disorders. Alcon Laboratories, Inc., assignee. US Patent 5,475,034. December 12, 1995.
- OgawaTMiyakeKMcNamaraTRPharmacokinetic profile of topically applied bromfenac sodium ophthalmic sodium ophthalmic solution 0.1% in subjects undergoing cataract surgeryProceedings of the Association for Research in Vision and Ophthalmology (ARVO) Annual MeetingFt. Lauderdale, FLApril 30–May 4, 2006A687
- BakalyanGADeshmukhHMPattersonHConcentrations of radioactivity in ocular tissues after a single topical dose of Cbromfenac ophthalmic solutionProceedings of the American Society of Cataract and Refractive Surgery (ASCRS) MeetingSan Francisco, CAMarch 17–22, 2006Abstract p. 227.
- HelbergMRNixonJCUse of non-steroidal anti-inflammatory agents in combination with compounds that have PF prostaglandin agonist activity to treat glaucoma and ocular hypertension. Alcon Laboratories, Inc., assignee. US Patent 6,342,524 B1. January 29, 2002.
- McNamaraTRBaklayanGADeshmukhHMConcentrations of radioactivity in ocular tissues after a single 0.09% topical dose of C-bromfenac ophthalmic solutionProceedings of the Association for Research in Vision and Ophthalmology (ARVO) Annual MeetingFt. Lauderdale, FLApril 30–May 4, 2006A687
- MasudaKFukadoYShimizuHEffect of bromfenac sodium ophthalmic solution on inflammation following intraocular lens implantationGanka Rinsho Iho (Jpn Rec Vin Ophthalmol)199791745750
- WaltersTRaizmanMErnestPGaytonJLehmannRIn vivo pharmacokinetics and in vitro pharmacodynamics of nepafenac, amfenac, ketorolac, and bromfenacJ Cataract Refract Surg20073391539154517720067
- BucciFWaterburyDComparison of ketorolac 0.4% and bromfenac 0.09% at trough dosing: Aqueous drug absorption and prostaglandin E2 levelsJ Cataract Refract Surg2008341509151218721711
- KawaguchiTKidaTNemotoSEffect of bromfenac ophthalmic solution on ocular inflammation and corneal epithelial barrier function following cataract surgeryFolia Ophthalmol Jpn200354276279
- TakamatsuFShiroyamaNSaitoYEfficacy and adverse effects of bromfenac ophthalmic solution following cataract surgery. Rinsho Ganka(Jpn J Clin Ophthalmol)20035712331237
- OharaKOhkubaAMiyamotoTEffect of bromfenac sodium on postoperative inflammationJpn J Catarac Refract Surg200418112
- DonnenfeldEDHollandEJStewartRHGowJAGrilloneLRBromfenac Ophthalmic Solution 0.09% (Xibrom) Study GroupBromfenac ophthalmic solution 0.09% (Xibrom) for postoperative ocular pain and inflammationOphthalmology200711491653166217445902
- StewartRHGrilloneLRShiffmanMLDonnenfeldEDGowJABromfenac Ophthalmic Solution 0.09% Study GroupThe systemic safety of bromfenac ophthalmic solution 0.09%J Ocul Pharmacol Ther200723660161218001250
- GreavesRRAgarwalAPatchDInadvertent diclofenac rechallenge from generic and non-generic prescribing, leading to liver transplantation for fulminant liver failureEur J Gastroenterol Hepatol200113717311204815
- AithalGPDiclofenac-induced liver injury: A paradigm of idiosyncratic drug toxicityExp Opin Drug Saf20043519523
- MacarioALipmanAGKetorolac in the era of cyclo-oxygenase-2 selective nonsteroidal anti-inflammatory drugs: A systematic review of efficacy, side effects, and regulatory issuesPain Med2001233635115102238
- WaterburyLDMarked contralateral activity of bromfenac in a rabbit model of ocular inflammationInvest Ophthalmol Vis Sci200546: Abstract 3936.
- National PBM Drug Monograph, Bromfenac 0.09% Ophthalmic Solution (Xibrom®) June 2006. Available from: http://www.pbm.va.gov/monograph/Bromfenac0.09PercentOphthalmicSolution.pdf
- LinJCRapuanoCJLaibsonPRCorneal melting associated with use of topical nonsteroidal anti-inflammatory drugs after ocular surgeryArch Ophthalmol20001181129113210922213
- CongdonNGScheinODvon KulajtaPCorneal complications associated with topical ophthalmic use of nonsteroidal anti-inflammatory drugsJ Cataract Refract Surg20012762263111311634
- FlachAJCorneal melts associated with topically applied non-steroidal anti-inflammatory drugsTrans Am Ophthamol Soc200199205212
- GuideraACLuchsJIUdellIJKeratitis, ulceration, and perforation associated with topical nonsteroidal anti-inflammatory drugsOphthalmology200110893694411320025
- MianSIGuptaAPinedaRIICorneal ulceration and perforation with ketorolac tromethamine (Acular) use after PRKCornea20062523223416371790
- WolfEJKleimanLZSchrierANepafenac-associated corneal meltJ Cataract Refract Surg200733111974197517964407
- AsaiTNakagamiTMochizukiMThree cases of corneal melting after instillation of a new nonsteroidal anti-inflammatory drugCornea20062522422716371788
- IsawiHDhaliwalDKCorneal melting and perforation in Stevens Johnson syndrome following topical bromfenac useJ Cataract Refract Surg20073391644164617720085
- HashizumeNSaikaSOkadaYEffects of anti-inflammatory drugs on migration of the rabbit corneal epitheliumJ Cataract Rrefract Surg20012714991502
- HershPSRiceBABaerJCTopical nonsteroidal agents and corneal would healingArch Ophthalmol19901085775832322160
- KitaoNShimojiHFukudaMPostmarketing surveillance of bromfenac sodium (Bronuck) ophthalmic solutionJn Eye20052212991308
- TaylorSAGalbraithSMMillsRPCauses of non-compliance with drug regimens in glaucoma patients: a qualitative studyJ Ocul Pharmacol Ther20021840140912419091
- PatelSCSpaethGLCompliance in subjects prescribed eye drops for glaucomaOphthalmic Surg1995262332367651690
- ChaSHLeeJSOumBSKimCDCorneal epithelial cellular dysfunction from benzalkonium chloride (BAC) in vitroClin Experiment Ophthalmol20043218018415068436
- FlachAJCyclooxygenase inhibitors in ophthalmologySurv Ophthalmol1992Jan–Feb3642592841549810
- FlachAJThe incidence, pathogenesis, and treatment of cystoids macular edema following cataract surgeryTrans Am Ophthalmol Soc19989655763410360304
- QuinnCJCystoid macular edemaOptom Clin1996511111308963073
- TranosPGWickremasingheSSStangosNTTopouzisFTsinopoulosIPavesioCEMacular edemaSurvev Ophthalmol200449470490
- ColinJThe role of NSAIDs in the management of postoperative ophthalmic inflammationDrugs20076791291130817547472
- RobertsCWPretreatment with topical diclofenac sodium to decrease postoperative inflammationOphthalmology19961036366398618764
- RaySD’AmicoDJPseudophakic macular edemaSemin Ophthalmol20021716718012759847
- UrsellPGSpaltonDJWhitcupSMNussenblattRBCystoid macular edema after phacoemulsification: relationship to blood-aqueous barrier damage and visual acuityJ Cataract Refract Surg199925111492149710569164
- MentesJErakgunTAfrashiFKerciGIncidence of cystoids macular edema after uncomplicated phacoemulsificationOphthalmologica2003217640841214573973
- GulkilikGKocaboraSTaskapiliMEnginGCystoid macular edema after phacoemulsification: risk factors and effect on visual acuityCan J Ophthalmol2006469970317224950
- SivaprasadSMcCluskeyPLightmanSIntravitreal steroids in the management of macular oedemaActa Ophthalmol Scand20068472273317083528
- MiyakeKPrevention of cystoid macular edema after lens extraction by topical indomethacin (I). A preliminary reportGraefes Arch Klin Exp Ophthalmol19772038188
- FlachAJDolanBJIrvineAREffectiveness of ketorolac tromethamine 0.5% ophthalmic solution for chronic aphakic and pseudophakic cystoid macular edemaAm J Ophthalmol19871034794863551617
- McColginAZRaizmanMBEfficacy of topical Voltaren in reducing the incidence of postoperative cystoid macular edemaInvest Ophthalmol Vis Sci199940Suppl2899950586
- GrossJGXibrom (bromfenac) reduces cystoid macular edema associated with vein occlusions, macular epiretinal membrane, diabetic retinopathy and age related macular degenerationPoster F-3 presented at: Annual Meeting of the Retina SocietySeptember 27–30Boston
- RhoDSSollSMMarkovitzBJBromfenac 0.09% versus diclofenac sodium 0.1% verseus ketorolac tromethamine 0.5% in the treatment of acute pseudophakic cystoids macular edema: diclofenac versus ketorolacProceedings of the Association for Research in Vision and Ophthalmology (ARVO) Annual MeetingFt. Lauderdale, FLApril 30–May 4, 2006AF211
- OharaKOhkuboAMiyamotoTPrevention of miosis during cataract surgery by topical bromfenac sodiumRinsho Ganka (Jpn J Clin Ophthalmol)20045813251328
- Miyake-KashimaMTakanoYTanakaMComparision of 0.1% bromfenac sodium and 0.1% pemirolast potassium for the treatment of allergic conjunctivitisJpn J Ophthalmol20044858759015592786
- UsuiMMasudaKEffect of bromfenac sodium (AHR-10282B) eye drops on anterior uveitisGanka Rinsho Iho (J Rev Clin Ophthalmol)1997913944
- FitzGeraldGAPatronoCThe coxibs, selective inhibitors of cyclooxygenase-2N Engl J Med2001345643344211496855